{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Finside-biotech.simplecast.com%2Fepisodes%2Fbiotech-investment-trends-in-2026-fyhi6l0u","width":444,"version":"1.0","type":"rich","title":"Biotech Investment Trends in 2026","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/c69d1a1b-bbd0-4a07-b2e7-36cf948c6117/cropped_1791047609557.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/6dbace7a-8b92-4b60-ac24-92b2f17cf544\" height=\"200\" width=\"100%\" title=\"Biotech Investment Trends in 2026\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode of Inside Biotech, we sit down with Eileen, a UC Irvine PhD candidate and member of the BCLA Consulting team, to explore biotech investment trends across the U.S. in 2026. We discuss shifts in early- and late-stage venture funding, the rise of licensing and M&A activity, growing investment in AI and biologics, and changing trends across therapeutic modalities. Eileen also shares insights from BCLA’s Card News research and discusses what these trends could mean for biotech startups, investors, consultants, and the future of innovation.\n\nBCLA Card News: https://www.bc-la.org/about-3"}